dapirolizumab pegol

Home
Ligands
dapirolizumab pegol

GtoPdb Ligand ID: 11123

Synonyms: CDP-7657 | CDP7657 | DZP

Comment: Dapirolizumab pegol (CDP7657) is a pegylated monovalent Fab' immunomodulator that targets CD40 ligand [1]. It was developed by UCB Pharma. Removal of the Fc domain prevented the increased risk of thrombotic events observed with an intact mAb.

References
1. Shock A, Burkly L, Wakefield I, Peters C, Garber E, Ferrant J, Taylor FR, Su L, Hsu YM, Hutto D et al.. (2015) CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther, 17: 234. [PMID:26335795]
2. Tocoian A, Buchan P, Kirby H, Soranson J, Zamacona M, Walley R, Mitchell N, Esfandiari E, Wagner F, Oliver R. (2015) First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus, 24 (10): 1045-56. [PMID:25784719]

References

1. Shock A, Burkly L, Wakefield I, Peters C, Garber E, Ferrant J, Taylor FR, Su L, Hsu YM, Hutto D et al.. (2015)
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
Arthritis Res Ther, 17: 234. [PMID:26335795]

2. Tocoian A, Buchan P, Kirby H, Soranson J, Zamacona M, Walley R, Mitchell N, Esfandiari E, Wagner F, Oliver R. (2015)
First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus.
Lupus, 24 (10): 1045-56. [PMID:25784719]